Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

697
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
697
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

563
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
563
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

384
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
384
Drug Elimination by Renal Route: Tubular Secretion01:15

Drug Elimination by Renal Route: Tubular Secretion

2.4K
Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
2.4K
Renal Drug Excretion: Tubular Reabsorption01:25

Renal Drug Excretion: Tubular Reabsorption

183
Tubular reabsorption, a process occurring post-glomerular filtration of drugs in the renal tubule, is a critical determinant of drug half-life. During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. This...
183
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

631
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
631

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association between Torque teno virus-DNA plasma loads and post-transplantation diabetes mellitus in the first year after kidney transplantation.

BMC nephrology·2026
Same author

Renal transplantation in older recipients - results of the DZIF transplant cohort.

BMC geriatrics·2026
Same author

Unhealthy fat distribution as a sex-specific predictor of declining hippocampus insulin sensitivity.

Diabetologia·2026
Same author

Pathogen-specific epidemiology and clinical trajectories of fungal infections after kidney transplantation: a prospective multicenter cohort study.

BMC infectious diseases·2026
Same author

Effect of Finerenone on Albuminuria in Type 1 Diabetes by Baseline HbA1c Level and Diabetes Duration: An Exploratory Analysis of the FINE-ONE Trial.

Diabetes care·2026
Same author

Cancer prevention through metabolic remission.

Nature reviews. Endocrinology·2026

Related Experiment Video

Updated: Jul 5, 2025

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
07:38

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Published on: May 6, 2018

8.4K

SGLT2 Inhibitors Decrease Overhydration and Proteasuria in Patients with Chronic Kidney Disease: A Longitudinal

Anja Schork1,2,3, Marie-Luise Eberbach1, Bernhard N Bohnert1,2,3

  • 1Division of Endocrinology, Diabetology and Nephrology, Department of Internal Medicine IV, University Hospital Tübingen, Tübingen, Germany.

Kidney & Blood Pressure Research
|January 16, 2024
PubMed
Summary
This summary is machine-generated.

Sodium-glucose cotransporter 2 (SGLT2) inhibitors effectively reduce overhydration in chronic kidney disease (CKD) patients. This effect is more pronounced with higher levels of albuminuria and glucosuria.

Keywords:
Bioimpedance spectroscopyBody compositionChronic kidney diseaseOverhydrationProteasuriaSGLT2 inhibitor

More Related Videos

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
08:50

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat

Published on: July 3, 2013

23.6K
Assessment of Kidney Function in Mouse Models of Glomerular Disease
09:16

Assessment of Kidney Function in Mouse Models of Glomerular Disease

Published on: June 30, 2018

17.7K

Related Experiment Videos

Last Updated: Jul 5, 2025

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
07:38

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Published on: May 6, 2018

8.4K
5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
08:50

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat

Published on: July 3, 2013

23.6K
Assessment of Kidney Function in Mouse Models of Glomerular Disease
09:16

Assessment of Kidney Function in Mouse Models of Glomerular Disease

Published on: June 30, 2018

17.7K

Area of Science:

  • Nephrology
  • Pharmacology
  • Cardiorenal Medicine

Background:

  • Chronic kidney disease (CKD) is frequently associated with extracellular volume expansion and overhydration (OH).
  • SGLT2 inhibitors are established treatments for reducing CKD progression and have demonstrated effects on extracellular volume in type 2 diabetes patients.

Purpose of the Study:

  • To investigate the efficacy of SGLT2 inhibitors in correcting overhydration (OH) in patients with chronic kidney disease (CKD).

Main Methods:

  • Prospective observational study of CKD patients over 6 months following initiation of SGLT2 inhibitor therapy.
  • Body composition and fluid status assessed using bioimpedance spectroscopy.
  • Urinary analysis included albuminuria, glucosuria, and protease activity.

Main Results:

  • SGLT2 inhibitors significantly reduced OH by 0.5 L/1.73 m2 after 6 months in CKD patients.
  • The reduction in OH correlated with baseline OH levels, decreased albuminuria, glucosuria, and urinary protease activity.
  • No significant reduction in adipose tissue mass was observed.

Conclusions:

  • SGLT2 inhibitors are effective in reducing overhydration (OH) in patients with CKD.
  • The beneficial effect on OH is more pronounced in patients with high albuminuria, glucosuria, and specific urinary protease activity.